Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Inamoto, Yoshihiro; Valdés-Sanz, Nuria; Ogawa, Yoko; Alves, Monica; Berchicci, Luigi; Galvin, John; Greinix, Hildegard; Hale, Gregory A; Horn, Biljana; Kelly, Debra; Liu, Hien; Rowley, Scott; Schoemans, Helene; Shah, Ami; Lupo Stanghellini, Maria Teresa; Agrawal, Vaibhav; Ahmed, Ibrahim; Ali, Asim; Bhatt, Neel; Byrne, Michael; ... (2018). Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biology of blood and marrow transplantation, 25(2), e46-e54. Elsevier 10.1016/j.bbmt.2018.11.021

[img] Text
1-s2.0-S1083879118307547-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (488kB)

Ocular graft-versus-host disease (GVHD) occurs in more than one-half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity that affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed. Ocular GVHD involves at least 3 biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have identified several novel pathogenic mechanisms, including the renin angiotensin system and endoplasmic reticulum stress signaling, which can be targeted by therapeutic agents. Numerous studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. The efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important that all health professionals caring for HCT recipients have adequate knowledge of ocular GVHD to provide optimal care.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Rovó, Alicia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1083-8791

Publisher:

Elsevier

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

31 Jan 2019 11:40

Last Modified:

05 Dec 2022 15:24

Publisher DOI:

10.1016/j.bbmt.2018.11.021

PubMed ID:

30481594

Uncontrolled Keywords:

Biology Chronic graft-versus-host disease Eye Hematopoietic cell transplantation Review Treatment

BORIS DOI:

10.7892/boris.123280

URI:

https://boris.unibe.ch/id/eprint/123280

Actions (login required)

Edit item Edit item
Provide Feedback